具有可替换匹配的链间半胱氨酸的双特异性抗体及其用途
By introducing specific amino acid substitutions into bispecific antibodies to form new interchain disulfide bonds, the mismatch problem in the production process was solved, the stability of the antibodies and their ability to target cancer cells were improved, and the therapeutic effect was enhanced.
CN114929739BActive Publication Date: 2026-07-17PHANES THERAPEUTICS INC
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- PHANES THERAPEUTICS INC
- Filing Date
- 2020-12-03
- Publication Date
- 2026-07-17
AI Technical Summary
Technical Problem
Existing bispecific antibodies are prone to mismatch during the production process, making it difficult to effectively target cells with two different antigens, and they also have low stability and production efficiency.
Method used
By introducing specific amino acid substitutions or mutations into the heavy and light chains of bispecific antibodies, new interchain disulfide bonds are formed to stabilize the antibody structure and promote heterodimer formation, binding specific antigens, including CD47 and FRα.
Benefits of technology
It improved the stability and production efficiency of bispecific antibodies, enhanced the targeting ability of cancer cells expressing CD47 and FRα, reduced the binding to normal cells, and enhanced the therapeutic effect.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure CN114929739B_ABST
Abstract
描述了在一个臂上具有移位的链间二硫键的同时在第二个臂上保持天然链间二硫键的工程化双特异性抗体。还描述了抗CD47 / FRα双特异性抗体及其抗原结合片段。还描述了编码该抗体的核酸、包含该抗体的组合物、以及制备该抗体和使用该抗体治疗或预防疾病如癌症和 / 或相关并发症的方法。
Need to check novelty before this filing date? Find Prior Art